🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congrats #MichaelOng SOUMYAJIT ROY for oral Ab#5002 ASCO #ASCO25👉bit.ly/43NyyfY👉Real-world IRONMAN registry of mHSPC #prostatecancer (n=1288 pts)👉PSA<0.02 after 6-12 mo of Rx had best prognosis (3-yr OS 92.7%)👇Dan George OncoAlert UroToday.com PCF Science

Outstanding work by Chris Booth and colleagues - major impact - and showing just what non pharmaceutical interventions can actually achieve!! World Health Organization (WHO) ASCO ESMO - Eur. Oncology

#ASCO25 @asco CCTG 🇨🇦 C0.21 CHALLENGE trial - ‘first-in-class’ RCT of 3y structured exercise program (>10 METhr/wk) vs education in stage 2/3 colon cancer after surgery & AT - Dr. Chris Booth 📌 N=889, 6 countries (>60% 🇨🇦), 90% stg 3 📌 improved DFS, HR 0.72 (p=0.0

If you are at #ASCO25 come check out Michael Ong present substudy C of the CCTG PC-BETS trial. Darolutamide for mCRPC with AR alterations based on ctDNA (Alex Wyatt)

During the last #ASCO25 session on Prostate Cancer, presentation of updated data on #IronMan trial w/ our Brazilian PI André P. Fay. Last day only for the brave ones! LACOG - Latin American Cooperative Oncology Group IRONMAN Registry

nice job by Michael Ong promoting the need to support TRIPLE-SWTICH… let’s see if acting on this PSA threshold is important. #ASCO25

📢 #ASCO25 | IRONMAN Registry: PSA Landmarks | Metastatic HSPC: In 1288 mHSPC patients on ADT +/- ARPI, 12 mo PSA > 0.2 predicts poor outcomes (3 year OS 45% vs 93% for PSA < 0.02; 3 year PFS 37% vs 93%); adjusted HR for death 7.34. Ph. III clinical trial TRIPLE SWITCH launching

Proud of my mentor Michael Ong presenting impt international #IRONMAN data: 🚹 mCSPC w/ ADT + ARPI 🌀PSA of >= 0.2 at 6-12mo = worse px (mOS 30mo) ➡️consider #TRIPLESWITCH intensification trial now open 🌀PSA<0.2 at 6-12mo = good px ➡️ consider #DEESCALATE trial #ASCO25

Congrats Michael Ong for the stellar talk ASCO #ASCO25 👉 PSA response (<0.2 ng/ml) after starting ADT+ARPI in mHSPC #prostatecancer (occurred in 50% of pts) associated with ⬆️OS (& 5-fold ⬆️ in death if PSA is >\=0.2). OncoAlert UroToday.com PCF Science Dan George

Another proud RadOncUH Chair moment to see our soon to be newest faculty SOUMYAJIT ROY being recognized for his statistical brilliance in collaboration with #IRONMAN #ASCO25 ASCO Way to go! Jason Brown Pedro C Barata, MD MSc FACP Jonathan Evan Shoag 🇮🇱🇺🇸 Lee Ponsky JAGarciaMD Dr. Theodoros Teknos

As shown by Michael Ong ASCO #asco25 👉 treatment escalation (SWOG Cancer Research Network Triple Switch/CCTG, and de-escalation trials have been started based on PSA response in mHSPC #prostatecancer OncoAlert UroToday.com PCF Science

The #IRONMAN registry with some practical updates on PSA response in metastatic hormone sensitive #prostatecancer — depth of PSA response matters — sets up current #TRIPLESWITCH trial in CCTG SWOG Cancer Research Network. Congrats Michael Ong & team. #ASCO25 UroToday.com

#ASCO25 Michael Ong fantastic presentation A#IRONMAN data #PSAmatters

Neeraj Agarwal, MD, FASCO Michael Ong ASCO SWOG Cancer Research Network OncoAlert UroToday.com PCF Science Sumanta K. Pal, MD, FASCO Toni Choueiri, MD Umang Swami Tanya Dorff Tian Zhang, MD, MHS GU Cancer Research Program @HuntsmanCancer Yüksel Ürün Zeynep Irem Ozay, MD Benjamin L Maughan Dra. María Natalia Gandur Quiroga What are you thoughts about this treament intensification strategy without considering biology in the light of STAMPEDE pten deficiency signature data and benefit of docetaxel/no benefit of ARPIs Neeraj Agarwal, MD, FASCO Daniel Castellano Yüksel Ürün Christopher Sweeney, MBBS Elena Castro Michael Ong

#ASCO25 IRONMAN register shows that deep responses in PSA mainly those < 0.2 mg/dl have a better prognosis, and brings an excellent proposal to de-escalation therapy in those patients OncoDaily OncoAlert Asociación Colombiana de Hematología y Oncología Sociedad Colombiana de Urología UroToday.com UroTarget 🦾🦾🦾